Veracyte saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an upgrade from 79 to 82.
IBD's unique RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks matches up against other publicly traded companies.
Decades of market research reveals that the market's biggest winners tend to have an 80 or better RS Rating as they begin their biggest climbs.
Risk Management In The Stock Market: How Much Money To Invest Now
Veracyte is not currently offering a proper buying opportunity. See if the stock goes on to build a sound pattern that could launch a new move.
Veracyte reported 71% earnings growth last quarter. Revenue increased 21%.
Veracyte holds the No. 2 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
